Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

• প্রধান লেখক: Ching‐Yu Wang (লেখক), Phuong N. Pham (লেখক), Sarah Kim (লেখক), Karthik Lingineni (লেখক), Stephan Schmidt (লেখক), Vakaramoko Diaby (লেখক), Joshua Brown (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2020-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Generic entry of newer anticoagulants is expected to decrease the costs of atrial fibrillation management. However, when making switches between brand and generic medications, bioequivalence concerns are possible. The objectives of this study were to predict and compare the lifetime cost‐effectivene...